Leila,
I'd like to assign you a research memorandum on IRC § 6662(e) penalty protection standards — specifically, the substantial valuation misstatement penalty as it applies in the transfer pricing context. This is for Matter 1018-00009 (Penterra Pharmaceuticals Corp., IRS examination defense, TY 2017–2020).
Leonard Cross has asked us to get ahead of this issue now. I know the examination is still in the IDR phase — we have 47 IDRs being processed since the exam opened on May 16, 2022 (Exam Team LB&I-NE-TP-2022-00641) — but penalty exposure could be significant if the IRS ultimately proposes adjustments, and Leonard wants us to have a clear picture of where we stand on penalty protection before the exam progresses further.
**Background**
PPC had contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (Susan Lam, Transfer Pricing Partner) for all four tax years (2017–2020). The documentation covers both the cost-sharing arrangement with PBI (CSA effective July 1, 2012; PBI cost-sharing percentages ranging from 38.2% to 42.7% across the years) and the legacy IP royalty arrangement (4.5% of net sales). The documentation was prepared under the penalty-protection standards of IRC § 6662(e) and the applicable regulations — Treas. Reg. § 1.482-7 for the CSA and § 1.482-4 for the royalty.
If the IRS ultimately proposes a § 482 allocation, the primary penalty risk is the 20% substantial valuation misstatement penalty under § 6662(e). The IRS could also potentially assert the 40% gross valuation misstatement penalty under § 6662(h), though that is obviously a higher bar. To give you a rough order of magnitude: based on the IRS exam team's apparent focus areas — the CSA cost-sharing ratios, the legacy IP royalty rate of 4.5%, and the PCT valuation ($312M payment) — we are anticipating that proposed adjustments could be in the hundreds of millions. A 20% penalty on the resulting tax would be substantial, so this is not an academic exercise.
**Scope of the Research Memorandum**
I'd like you to address the following:
**(a) Contemporaneous Documentation Requirements under IRC § 6662(e)(3)(B)**
What constitutes "contemporaneous documentation" sufficient to establish a reasonable-cause defense and penalty protection? Please cover timing requirements (when must the documentation be prepared and maintained), content requirements (functional analysis, method selection, comparable analysis, etc.), and how courts and the IRS have interpreted "substantially similar" documentation.
**(b) Reasonable Cause Defense**
Address the standards for establishing reasonable cause under § 6662(e), including the role of reliance on professional advisors. Here, Crestfield & Associates prepared the original contemporaneous documentation. I'd also like you to analyze whether engagement of outside counsel (i.e., our firm) and independent economists (Whitmore Valuation Group, retained under the Kovel arrangement, reference 1018-00009-KV) further supports a reasonable cause defense. Please identify and discuss relevant case law on reasonable cause in the transfer pricing penalty context.
**(c) Interaction with § 482 Methods**
How does penalty protection interact with the best method rule under Treas. Reg. § 1.482-1(d)? Specifically, analyze whether the use of the CUT method for the royalty rate — PPC's 4.5% rate is supported by 14 comparable uncontrolled pharmaceutical license agreements with an IQR of 3.1%–6.8% and a median of 4.4% — and CPM/TNMM for CSA participant testing (22 comparable companies) strengthens or complicates penalty protection. Also address documentation of the income method / DCF approach for the PCT valuation (the $312M payment, with the C&H/Whitmore range of $278M–$361M at a 9.8% WACC).
**(d) Net Adjustment Penalty vs. Transactional Penalty**
Does the penalty apply to the net § 482 allocation or on a transaction-by-transaction basis? This is particularly relevant here because the IRS exam team may allow correlative adjustments to avoid double-counting between the CSA and royalty adjustments.
**(e) Penalty Abatement at Appeals**
What are the frequency and standards for penalty abatement at IRS Appeals? Do Appeals Officers have independent authority to abate § 6662(e) penalties? Please review any guidance under Rev. Proc. 2015-41 and relevant IRM provisions on penalty consideration at Appeals, including the LB&I penalty approval procedures.
**Key Sources**
At a minimum, please review:
- IRC § 6662(e) and (h) - Treas. Reg. § 1.6662-6 (transfer pricing penalty regulations) - IRC § 6664(c) (reasonable cause exception) - Relevant portions of Treas. Reg. §§ 1.482-4, 1.482-7, and 1.482-1(d) - Case law — including any Tax Court or circuit court decisions addressing § 6662(e) penalties in the pharmaceutical or cost-sharing context - IRM provisions on LB&I penalty approval procedures - OECD Transfer Pricing Guidelines references to documentation standards (as persuasive authority, to the extent helpful)
**Existing Work Product**
You should review the Crestfield-prepared contemporaneous documentation that was already produced to the IRS in response to IDR No. 4 (produced August 1, 2022), as well as the original PCT valuation report and workpapers produced in response to IDR No. 5 (produced August 10, 2022). If you need access to the IDR tracker (the master log of all 47 IDRs) or the document production index, just let me know and I'll get you set up.
**Deliverable and Deadline**
I'm looking for a research memorandum of approximately 15–20 pages. Please have a draft to me by **Friday, November 18, 2022** — that gives you roughly three weeks, which I hope is manageable alongside your other matters. Leonard and Sylvia Hartwell will review the memo before it goes to the client (Marcus Whitfield, VP of Global Tax, and Deborah Staines, General Counsel at PPC). The memo will inform our overall defense strategy, so please treat it as attorney work product / privileged throughout.
If you have any questions about the scope or how to prioritize among the research questions, I'm happy to discuss. Let's plan on a brief check-in call early next week — I'll send a calendar invite for Monday or Tuesday.
Thanks for taking this on, Leila. I think this will be a really important piece of the overall defense.
Best, Garrett
Garrett Simmons Associate Calderwood & Harkness LLP gsimmons@calderwoodharkness.com